SC 13G: GILEAD SCIENCES, INC.
Ticker: GILD · Form: SC 13G · Filed: 2024-02-20T00:00:00.000Z
Sentiment: neutral
Topics: sc-13g
AI Summary
SC 13G filing by GILEAD SCIENCES, INC..
Risk Assessment
Risk Level: low
From the Filing
0001193125-24-040028.txt : 20240220 0001193125-24-040028.hdr.sgml : 20240220 20240220163104 ACCESSION NUMBER: 0001193125-24-040028 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240220 DATE AS OF CHANGE: 20240220 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Kyverna Therapeutics, Inc. CENTRAL INDEX KEY: 0001994702 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 831365441 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-94441 FILM NUMBER: 24653971 BUSINESS ADDRESS: STREET 1: 5980 HORTON STREET STREET 2: SUITE 550 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 5106268331 MAIL ADDRESS: STREET 1: 5980 HORTON STREET STREET 2: SUITE 550 CITY: EMERYVILLE STATE: CA ZIP: 94608 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 SC 13G 1 d665656dsc13g.htm SC 13G SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.  )* Kyverna Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 501976104 (CUSIP Number) February 12, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐ Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP NO. 501976104  1    NAMES OF REPORTING PERSONS   Gilead Sciences, Inc.  2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)  (a) ☐  (b) ☐  3   SEC USE ONLY  4   CITIZENSHIP OR PLACE OF ORGANIZATION   Delaware NUMBER OF SHARES  BENEFICIALLY  OWNED BY E ACH REPORTING PERSON WITH 5    SOLE VOTING POWER   4,126,119 6   SHARED VOTING POWER   0 7   SOLE DISPOSITIVE POWER   4,126,119 8   SHARED DISPOSITIVE POWER  0  9    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   4,126,119 10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  ☐ 11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)   9 . 6 % ( 1) 12   TYPE OF REPORTING PERSON*  CO (1) Percentage based on 42,997,525 shares of Common Stock outstanding, as disclosed in the Issuer’s prospectus filed with the U.S. Securities and Exchange Commission (“SEC”) pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended (the “Securities Act”), on February 8, 2024 and the Issuer’s Current Report on Form 8-K (“Form 8-